Loading companies…
Loading companies…
United Kingdom · Biotech · Healthtech · Enterprise software
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $115M | EQT Life Sciences — Role not disclosedForbion — Role not disclosedFrazier Life Sciences — Role not disclosedLifeArc — Role not disclosedMonograph — Role not disclosedOxford Science Enterprises — Role not disclosedOxford University Innovation — Role not disclosedWellington Management — Role not disclosed |